Paragon 28 Reports Preliminary Revenue Figures for Q4 and Full Year 2024

Paragon 28, Inc., a company specializing in foot and ankle healthcare solutions, recently disclosed its preliminary unaudited revenue for the fourth quarter and full year ending December 31, 2024. The announcement was made through a press release on January 13, 2025. The company’s unaudited revenue figures showcased steady growth, marking a significant achievement for Paragon 28 as it strives to enhance patient outcomes in the foot and ankle sector.

The press release included details on the company’s revenue performance over the specified periods. In addition to the press release, Paragon 28 also shared a comprehensive presentation on its website. This presentation delved into the financial profile of the company, its market strategy, product portfolio, and recent developments. Both the press release and the presentation provide valuable insights into Paragon 28’s operations and financial standing.

It’s important to note that the information disclosed in this report, including the press release and presentation, are not considered as filed reporting as per the requirements of the Securities Exchange Act of 1934. The details furnished in these documents are not subject to the liabilities outlined in the Act’s sections 18, 11, and 12(a)(2) of the Securities Act of 1933, nor are they meant to be incorporated by reference into future filings made by Paragon 28.

The company’s dedication to innovation and operational excellence is evident through its consistent product launches and commitment to advancing foot and ankle healthcare. Paragon 28’s strategic priorities include focusing on differentiated solutions and innovation, expanding sales channels, strengthening international presence, and driving operational efficiency and financial performance.

The financial statements and exhibits attached to the report provide a detailed overview of Paragon 28’s performance, including its revenue growth, strategic priorities, international presence, and operational efficiency. The company’s continued efforts to drive growth, deliver innovative healthcare solutions, and optimize its financial performance position it well for sustained success in the foot and ankle healthcare segment.

This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Paragon 28’s 8K filing here.

Paragon 28 Company Profile

Paragon 28, Inc develops, distributes, and sells foot and ankle surgical systems in the United States and internationally. It offers plating systems, including gorilla plating systems, such as lisfranc, lapidus, lateral column, calcaneus slide, and naviculocuneiform (NC) fusion plating systems; baby gorilla plate-specific screws, navicular fracture plates, and 5th metatarsal hook plates; and silverback plating systems.